BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $149.27M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.37M
Average 0.37M
Returns on capital
BridgeBio Oncology Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-32.6%
avg 20391.6%
ROIC
-35.2%
avg -198566.7%
ROA
-29.9%
avg -3907.2%
Analysis
ROA is currently the strongest return metric at -29.9% versus its period average of -3907.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Yong Ben | Chief Medical & Development Officer | USD 770.96K | 52 | 43.53K | 0.05% |
Pedro J. Beltran | Chief Executive Officer and Director | USD 767.66K | 55 | — | — |
Frank McCormick | Co-Founder, Non-Executive Director & Chair of the Advisory Board | USD 65K | 76 | 31.68K | 0.04% |
Neil Kumar | Executive Chairman | USD 20K | 47 | 31.68K | 0.04% |
Aaron Chan | Vice President of Legal | — | — | — | — |
Bin Wang | Senior Vice President of Drug Discovery | — | — | — | — |
Rui Xu | Senior Vice President of Drug Discovery | — | — | — | — |
Daniel Watson | Senior Vice President of Chemistry, Manufacturing & Controls | — | — | — | — |
Idan Elmelech | Chief Operating Officer | — | 33 | 14.15K | 0.02% |
Marc Cobo | VP of Finance & Controller | — | 45 | 13.81K | 0.02% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 21, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does BridgeBio Oncology Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about BBOT's management, answered from reported figures.
Who manages BBOT?
BridgeBio Oncology Therapeutics Inc. (BBOT) lists 10 active executives. The top listed executive is Frank McCormick, Co-Founder, Non-Executive Director & Chair of the Advisory Board.
Are BBOT insiders buying or selling?
Recent insider activity shows net buying of $137.47M.
Continue the stock analysis
Jump to another research area for this company.